Genflow Biosciences PLC Announces Key SIRT6 Patent Application
Genflow Biosciences (LSE:GENF)(OTCQB:GENFF) announces the advancement of its SIRT6-related patent application to the national examination phase by the Japanese Patent Office. The patent, titled "Variants of SIRT6 for Use in Preventing and/or Treating Age-Related Diseases," was filed in May 2022 and is jointly owned by the University of Rochester, Columbia University, and Albert Einstein College of Medicine, with Genflow holding exclusive licensing rights.
The patent covers novel SIRT6 gene variants crucial for genomic stability, metabolic regulation, and healthy aging, forming the foundation of Genflow's therapeutic platform. This advancement in Japan, a key market with a rapidly aging population, represents a significant step in the company's international patent protection strategy.
Genflow Biosciences (LSE:GENF)(OTCQB:GENFF) annuncia il passaggio della sua domanda di brevetto relativa a SIRT6 alla fase di esame nazionale presso l'Ufficio Brevetti Giapponese. Il brevetto, intitolato "Varianti di SIRT6 per l'uso nella prevenzione e/o nel trattamento delle malattie legate all'invecchiamento", è stato depositato nel maggio 2022 ed è di proprietà congiunta dell'Università di Rochester, della Columbia University e dell'Albert Einstein College of Medicine, con Genflow che detiene i diritti di licenza esclusiva.
Il brevetto riguarda nuove varianti del gene SIRT6, fondamentali per la stabilità genomica, la regolazione metabolica e un invecchiamento sano, costituendo la base della piattaforma terapeutica di Genflow. Questo progresso in Giappone, un mercato chiave con una popolazione in rapido invecchiamento, rappresenta un passo importante nella strategia internazionale di protezione brevettuale dell'azienda.
Genflow Biosciences (LSE:GENF)(OTCQB:GENFF) anuncia el avance de su solicitud de patente relacionada con SIRT6 a la fase de examen nacional por parte de la Oficina de Patentes de Japón. La patente, titulada "Variantes de SIRT6 para su uso en la prevención y/o tratamiento de enfermedades relacionadas con la edad", fue presentada en mayo de 2022 y es propiedad conjunta de la Universidad de Rochester, la Universidad de Columbia y el Albert Einstein College of Medicine, con Genflow poseyendo los derechos exclusivos de licencia.
La patente cubre nuevas variantes del gen SIRT6, cruciales para la estabilidad genómica, la regulación metabólica y un envejecimiento saludable, que forman la base de la plataforma terapéutica de Genflow. Este avance en Japón, un mercado clave con una población que envejece rápidamente, representa un paso significativo en la estrategia internacional de protección de patentes de la compañía.
Genflow Biosciences (LSE:GENF)(OTCQB:GENFF)는 일본 특허청에서 SIRT6 관련 특허 출원이 국가 심사 단계로 진전되었음을 발표했습니다. "노화 관련 질병 예방 및/또는 치료에 사용되는 SIRT6 변이체"라는 제목의 이 특허는 2022년 5월에 출원되었으며 로체스터 대학교, 콜롬비아 대학교, 알버트 아인슈타인 의과대학이 공동 소유하고 있으며, Genflow가 독점 라이선스 권리를 보유하고 있습니다.
이 특허는 유전체 안정성, 대사 조절 및 건강한 노화에 중요한 새로운 SIRT6 유전자 변이체를 포함하며, Genflow의 치료 플랫폼의 기초를 형성합니다. 급속히 고령화되는 인구를 가진 주요 시장인 일본에서의 이번 진전은 회사의 국제 특허 보호 전략에 중요한 단계입니다.
Genflow Biosciences (LSE:GENF)(OTCQB:GENFF) annonce l’avancement de sa demande de brevet liée à SIRT6 à la phase d’examen national par l’Office des brevets japonais. Le brevet, intitulé « Variantes de SIRT6 pour une utilisation dans la prévention et/ou le traitement des maladies liées à l’âge », a été déposé en mai 2022 et est détenu conjointement par l’Université de Rochester, l’Université de Columbia et le Albert Einstein College of Medicine, Genflow détenant les droits exclusifs de licence.
Le brevet couvre de nouvelles variantes du gène SIRT6, essentielles pour la stabilité génomique, la régulation métabolique et un vieillissement en bonne santé, constituant la base de la plateforme thérapeutique de Genflow. Cette avancée au Japon, un marché clé avec une population vieillissante rapidement, représente une étape importante dans la stratégie internationale de protection par brevet de la société.
Genflow Biosciences (LSE:GENF)(OTCQB:GENFF) gibt bekannt, dass seine SIRT6-bezogene Patentanmeldung von der japanischen Patentbehörde in die nationale Prüfungsphase übergegangen ist. Das Patent mit dem Titel "Varianten von SIRT6 zur Verwendung bei der Vorbeugung und/oder Behandlung altersbedingter Krankheiten" wurde im Mai 2022 eingereicht und befindet sich im gemeinsamen Eigentum der University of Rochester, der Columbia University und des Albert Einstein College of Medicine, wobei Genflow exklusive Lizenzrechte hält.
Das Patent umfasst neuartige SIRT6-Genvarianten, die für die genomische Stabilität, Stoffwechselregulation und gesundes Altern entscheidend sind und die Grundlage der therapeutischen Plattform von Genflow bilden. Dieser Fortschritt in Japan, einem wichtigen Markt mit schnell alternder Bevölkerung, stellt einen bedeutenden Schritt in der internationalen Patentstrategie des Unternehmens dar.
- Exclusive licensing rights secured for SIRT6 patent application
- Strategic expansion of patent protection in Japan, a key market for longevity treatments
- Advancement to national examination phase indicates patent progress
- Patent is still in examination phase, not yet granted
- Patent ownership is shared between multiple institutions
LONDON, UNITED KINGDOM / ACCESS Newswire / May 15, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), the only publicly listed longevity company in Europe, announces that the Japanese Patent Office has advanced its SIRT6-related patent application (Application No. JP 2024515284) to the national examination phase.
The application, titled "Variants of SIRT6 for Use in Preventing and/or Treating Age-Related Diseases," was originally filed on 13 May 2022 and is jointly owned by the University of Rochester, The Trustees of Columbia University in the City of New York, and Albert Einstein College of Medicine. Genflow holds the exclusive license to this intellectual property.
The invention covers novel SIRT6 gene variants that play a central role in genomic stability, metabolic regulation, and healthy aging. These variants underpin Genflow's core therapeutic platform and represent a key part of its pipeline targeting age-related diseases.
The progression to national examination in Japan marks an important step in Genflow's strategy to establish broad international patent protection. Japan, with one of the world's most rapidly aging populations, is a priority market for longevity-related innovation.
Dr. Eric Leire, CEO of Genflow Biosciences, commented: "We are pleased to see continued momentum in the protection of our SIRT6 intellectual property. Japan represents a strategically important jurisdiction for Genflow, and advancing this patent application strengthens our global positioning as a leader in longevity gene therapy."
Genflow continues to progress its preclinical and clinical programs targeting age-related pathologies using the SIRT6 gene variants.
Contacts
Genflow Biosciences | Harbor Access | ||
Dr Eric Leire, CEO | Jonathan Paterson, Investor Relations | ||
+32-477-495-881 | +1 475 477 9401 | ||
Corporate Brokers | |||
Capital Plus Partners Ltd | |||
Jon Critchley, +44 0203 821 6168 | |||
About Genflow Biosciences
Founded in 2020, Genflow Biosciences Plc. (LSE:GENF)(OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Expected to begin in 2025, Genflow's clinical trial aims to explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit www.genflowbio.com and follow the Company on LinkedIn and Twitter/X.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Genflow Biosciences PLC
View the original press release on ACCESS Newswire
FAQ
What is the significance of GENFF's SIRT6 patent application in Japan?
Who owns the SIRT6 patent application filed by Genflow Biosciences?
What is the potential market impact of GENFF's SIRT6 technology?
When was Genflow's SIRT6 patent application originally filed?
